Purdue Pharmaceuticals, L.P.
One Stamford Forum
About Purdue Pharmaceuticals, L.P.
Purdue Pharmaceuticals, L.P., headquartered in Stamford, CT, is a privately held pharmaceutical company founded by physicians and focused on meeting the needs of healthcare providers and the patients in their care. Together with its independent associated companies, Purdue is dedicated to finding, developing, and bringing to market new medicines and related products that improve health outcomes. The company has long been known for its pioneering research on persistent pain, a principal cause of human suffering.
Purdue also has a growing line of non-prescription products including laxatives, microbicides, and nutraceuticals. The company is dedicated to serving the evolving needs of healthcare providers, patients, and caregivers with prescription and non-prescription medicines. A commitment to innovation and caring spans every aspect of the organization, from discovering and launching new medicines to demonstrating their medical value.
Purdue has led the battle against inadequate treatment of pain by developing sustained-release medications to manage pain. Its sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to pain management.
In 1993, Purdue established Partners Against Pain® as a resource to help patients, caregivers, and healthcare professionals advance standards of pain care and alleviate unnecessary suffering through education and advocacy. Purdue has also assumed a leading role in addressing the serious public health problem of prescription drug abuse, supporting programs intended to help stem abuse.
At its research facilities in Cranbury, New Jersey, Purdue scientists are discovering new compounds to treat pain and developing formulations and delivery systems to help improve patient safety.
209 articles with Purdue Pharmaceuticals, L.P.
- Agreement resolves DOJ investigations into past marketing practices - Settlement funds primarily directed to state, local and tribal governments for opioid crisis abatement purposes - Agreement brings Purdue closer to its ultimate goal of delivering more than $10 billion in value to address the opioid crisis
The settlement stems from multi-year criminal and civil investigations into Purdue’s marketing practices related to its powerful prescription painkiller, OxyContin, which critics have argued facilitated the opioid epidemic.
The U.S. government is seeking $11 billion in civil and criminal penalties from Purdue Pharma as the maker of OxyContin winds its way through bankruptcy.
Purdue Pharma’s Avrio Health Donates Betadine® Antiseptic Products to Direct Relief for Use by Frontline Healthcare Workers
Avrio Health L.P., a subsidiary of Purdue Pharma L.P., has donated shipments of Betadine Solution and Surgical Scrub to Direct Relief, advancing the company’s previous commitment to donate $1.6 million worth of Betadine antiseptic products for use by frontline healthcare workers.
In light of the ongoing COVID-19 pandemic, the U.S. Bankruptcy Court for the Southern District of New York has granted a 30-day extension of the deadline to file a claim against Purdue Pharma L.P.,1 including claims related to Purdue prescription opioids, like OxyContin.2 The new deadline or "bar date" is Thursday, July 30, 2020, at 5:00 p.m..
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 20, 2020.
Purdue Pharma’s Avrio Health Begins Studies Assessing Betadine® (Povidone-Iodine) Antiseptic Products’ Safety and Effectiveness Against COVID-19
Program complements ongoing efforts to build understanding of potential virucidal properties of povidone-iodine against the virus causing COVID-19
Purdue Pharma’s Avrio Health Donates $1.6 Million Worth of Betadine® Antiseptic Products for Use by Frontline Healthcare Workers
Purdue Pharma’s Avrio Health Donates $1.6 Million Worth of Betadine ® Antiseptic Products for Use by Frontline Healthcare Workers
Those Who Believe They Have a Claim Against Purdue Must File a Proof of Claim by the Bar Date: June 30, 2020
Purdue Pharma L.P., a U.S. limited partnership, its general partner and its subsidiaries, including Imbrium Therapeutics L.P., Adlon Therapeutics L.P., Greenfield BioVentures L.P., Avrio Health L.P., Rhodes Technologies, and Rhodes Pharmaceuticals L.P., filed for bankruptcy in September 2019.
Purdue Taps Tom Vilsack, Former Cabinet Secretary and Governor, to Monitor Compliance With Voluntary Injunction
Feb. 21, 2020 15:13 UTC STAMFORD, Conn.--( BUSINESS WIRE )-- Purdue Pharma L.P. (“Purdue”) today announced the appointment of former United States Agriculture Secretary and Iowa Governor Tom Vilsack as Monitor under the voluntary self-injunction approved on November 6, 2019, in its chapter 11 bankruptcy case. In its initial bankruptcy filings, Purdue voluntarily proposed to formalize under court order its commitment to continue to refrain from engaging in certain promotional
Richard Sackler, the former president of Purdue Pharma, wanted prescribers to know that when it comes to treating pain, OxyContin was the way to go. And, in order to boost those sales, that meant the company had to downplay any concerns regarding the risk of addiction.
The bankruptcy court gave approval to the reimbursement of legal fees for states and local governments involved in the opioid lawsuit settlements, but with the understanding that would allow $200 million in emergency funds to flow to treatment programs.
New product is clinically proven to help treat colds when used at the first sign and help shorten the duration of a cold to help you feel better, faster!
Following Purdue Pharma’s Chapter 11 filing last month, other opioid makers are exploring ways to settle their own litigation problems by participating in the OxyContin drugmaker’s bankruptcy proceedings.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Days after reaching a tentative agreement with a majority of states involved in litigation against the company over its role in the opioid crisis in the United States, Purdue Pharmaceuticals filed Chapter 11 bankruptcy.
Meaningful settlement negotiations by Big Pharma could result in more rapid relief for distressed communities
Purdue Pharmaceuticals has reached a tentative settlement in thousands of opioid cases that could cost the company about $12 billion, but some litigation against the firm is expected to continue over its role in the opioid crisis.
Purdue Pharma may file for bankruptcy this week after negotiations over a multi-billion opioid claims settlement have stalled, multiple sources are reporting.
Citing unnamed sources “familiar with the matter,” Reuters said that the company will have no choice but to file for bankruptcy should a settlement not be agreed upon.